K160896 is an FDA 510(k) clearance for the ULTRASHAPE POWER SYSTEM. Classified as Focused Ultrasound For Tissue Heat Or Mechanical Cellular Disruption (product code OHV), Class II - Special Controls.
Submitted by Syneron Medical, Ltd. (Yokneam Illit, IL). The FDA issued a Cleared decision on July 8, 2016 after a review of 99 days - within the typical 510(k) review window.
This device falls under the General & Plastic Surgery FDA review panel, regulated under 21 CFR 878.4590 - the FDA general and plastic surgery device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.
Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the General & Plastic Surgery review framework, consistent with the majority of Class II 510(k) submissions.
View all Syneron Medical, Ltd. devices
NCT02154113
Completed
Interventional
Industry-sponsored
Ultrashape System in Combination With VelaShape II Device for Circumferential Reduction
Baseline Controlled Two-arm Multi-Center Study to Evaluate the Safety and Efficacy of Combined Multi-Focus Treatments of UltraShape® Contour I V3 System and VelaShape II Device for Non-Invasive Circumference Reduction
| Condition studied |
Abdominal Fat |
| Study design |
Parallel |
| Eligibility |
All sexes
· 18 Years+
· Healthy volunteers accepted
|
| Principal investigator |
Shlomit Mann |
| Sponsor |
Syneron Medical
(industry)
|
Started 2012-10-01
→
Primary completion 2013-08-01
→
Completed 2013-09-01
Primary outcome
Difference in circumference reduction between baseline and follow-up visits
Secondary outcome
Adverse Events
Study completed - no results published.
This trial concluded in 2013 but has not posted
results to ClinicalTrials.gov. Completed studies without public results are common
in industry-sponsored device trials; the data may be referenced in the
510(k) Summary PDF or remain unpublished.
View full study on ClinicalTrials.gov